Related Experiment Video
Updated: May 23, 2025

08:28
Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers
Published on: September 19, 2017
7.9K
Tunable G-Quadruplex Ligands: Azobenzene Derivatives for Light-Controlled DNA Modulation
Aleksandra Matusiak1, Mateusz Drąg1, Marco Deiana1
1Institute of Advanced Materials, Faculty of Chemistry, Wrocław University of Science and Technology, Wyb. Wyspiańskiego 27, 50-370, Wrocław, Poland.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|March 10, 2025
Summary
Researchers developed photoactive G-quadruplex (G4) ligands using azobenzene compounds. These light-switchable ligands offer tunable on-off control for precise G4 structure modulation in biological systems.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Molecular Biology
Background:
- Guanine-rich sequences form G-quadruplexes (G4s) during DNA processes.
- G4s are therapeutic targets in cancer due to their role in replication stress.
- Existing G4 ligands have permanent effects; light-switchable systems offer better control.
Purpose of the Study:
- To design and synthesize novel photoactive G4 ligands based on azobenzene.
- To investigate how structural variations (substitution, size, electronics) affect G4 binding and stabilization.
- To explore bidirectional modulation of G4 properties using external stimuli like light.
Main Methods:
- Synthesis of diverse azobenzene-based compounds.
- Orthogonal biophysical methods for G4 interaction analysis.
- Quantum-chemical calculations to understand structure-activity relationships.
Main Results:
- Azobenzene substitution patterns influence G4 binding and stabilization.
- The trans isomer's interaction mode bidirectionally modulates G4 properties.
- Photoactivity allows for tunable on-off control of G4 ligands.
Conclusions:
- Insights into designing photoactive G4 ligands with tunable functionality.
- Potential for precise control of G4 structures in biological applications.
- Azobenzene-based compounds are promising candidates for light-switchable G4-targeting therapies.

